- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI to begin phase-III trials for FS069
Molecular Biosystems of San Diego plans to begin phase-III clinicaltrials for its FS069 second-generation ultrasound contrast agent.MBI said this month that 200 patients undergoing echocardiographywill be studied for the agent's ability to provide left
Molecular Biosystems of San Diego plans to begin phase-III clinicaltrials for its FS069 second-generation ultrasound contrast agent.MBI said this month that 200 patients undergoing echocardiographywill be studied for the agent's ability to provide left ventricularopacification and to enhance endocardial border delineation. MBIdeveloped Albunex, which is marketed in the U.S. by MallinckrodtMedical. Mallinckrodt also has marketing rights to FS069 (SCAN9/13/95).
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
